Analyst Conference Summary

biotechnology

conference date: August 13, 2026 @ 5:30 AM Pacific Time
for quarter ending: June 30, 2026 (second quarter, Q2)

Forward-looking statements

Overview:

Basic data (GAAP):

Revenue was zero.

Net income, diluted, was negative $ million, down sequentially from negative $2.7 million, and up from negative $ million year-earlier.

EPS (earnings per share), diluted, was negative $, down sequentially from negative $0.57, and up from negative $0 year-earlier.

Guidance:

Cash runway for at least next 12 months.

Conference Highlights:

Dr. Jennifer Buell, President and CEO of MiNK said: ""

iNKT (invariant natural killer T) cells have unique regulatory and immune functions. agenT-797 has shown the ability to restore immune function and is now positioned as a platform therapeutic. MiNK is the international leader in this field.

Financial execution was very disciplined. High capital efficiency, including the study in Ukraine.

In March 2026 announced PRAME-TCR-engineered iNKT advancing under the C-Further Consortium collaboration. This provides up to $1.1 million in non-dilutive funding plus meaningful double-digit percentage revenue share. See MiNK Pediatric Cancers announcement.

Melissa Orillal was appointed Principal Financial Officer in Q1 2026.

In Q1 agenT-797 began a Phase 2 trial for severe acute lung injury and critical illness for ARDS, including acute hypoxemic respitory failure from pneumonia. Designed to roll seamlessly into Phase 3. International trial (US and Ukraine) with preliminary data in 2H 2026. See May 14 2026 MiNK Therapeutics press release.

In Q1 data from the Phase 2 trial in PD-1 refractory gastoesophageal cancer that showed 77% disease control and PFS, in the primed subgroup, of 6.9 months, v. 3.5 months in the control group. Data presented at ASGCT. Missed primary endpoint, but showed long-term survival in the subgroup of patients treated with immune induction prior to chemotherapy. Also at ASGCT showed disctinct immune outputs in ARDS patients v cancer patients. See MiNK Therapeutics at ASGCT 2026

Current externally supported programs include its graft-versus-host disease program supported by NIH STTR funding and the Mary Gooze philanthropic award.

In Q2, on May 20, 2026, MiNK will present agenT-797 (with an IL agonist) clinical data for unresolving coccidioides immitits infection at the American Thoracic Society conference. Partner is Immunity Bio.

In 1H 2026 agenT-797 advanced in a randomized Phase 2 in hypoxemic pneumonia/ARDS, a severe inflammatory condition. Early data by year end. Market opportunity is 200,000 to 300,000 patients annually in US/EU.

Strategic discussions to advance agent-797 in end stage pulmonary fibrosis (IPF) are actively underway.

MiNK has not confirmed some announcements of clinical partnerships by others, but will keep investors informed of developments.

MiNK-215, a novel FAP-CAR-iNKT, presented preclinical data at AACR in MSS colorectal cancer liver metastases in April 2024. MiNK-215 IND filing planned. Further advancement of the program is expected in 2026.

MiNK-413, is a differentiated FAP allogeneic armored-BCMA-CAR-iNKT, in preclinical development.

Mink Therapeutics ended the quarter with a cash balance of $9.5 million, down sequentially from $13.4 million. Raised an additional $3 million cash raised in Q1 2026 using the ATM. It also repaid $5.2 million on the Agenus convertible note.

Operating expenses were not given. $ million, consisting of: R&D $ million; G&A $ million. Change in fair value $ million. Other expense $ million.

Q&A selective summary:

OpenIcon Analyst Conference Summaries Main Page

Search

More Analyst Conference Pages: